#Canada #Toronto #Minimal Residual Disease #Oncology Trials #Syneos Health

Webinar on Minimal Residual Disease (MRD) in Oncology Trials

In the rapidly evolving field of oncology, the concept of Minimal Residual Disease (MRD) is becoming increasingly crucial. This upcoming free webinar, hosted by Xtalks, is designed for professionals seeking to enhance their understanding of MRD's role within oncology programs. Participants will receive a comprehensive overview of where MRD fits in, particularly concerning dose escalation, optimization, and regulatory strategies.

Why MRD Matters

Minimal Residual Disease refers to the small number of cancer cells that may remain in a patient's body after treatment, which could lead to relapse if not properly addressed. Traditionally regarded as a marker mainly in hematologic cancers, MRD is now recognized as an essential factor influencing broader oncology development strategies. By enabling earlier readouts of therapeutic efficacy and improving patient stratification, MRD facilitates more efficient trial designs and outcomes.

Webinar Overview

The event promises to equip attendees with insights on the latest regulatory and clinical pharmacology considerations when utilizing MRD as a biomarker. Key topics to be covered include:

• - Assay Selection and Timing: Understanding the practical procedures involved in the selection of MRD assays and the significance of sample collection timing.
• - Regulatory Guidance: Insights into what regulators expect concerning MRD and the evidence required to substantiate its use in clinical trials.
• - Cross-functional Governance: Exploring the need for strong collaboration among teams to interpret MRD results in conjunction with imaging and clinical response data effectively.

Experts from Syneos Health will lead the session, including notable figures like Wael Harb, MD, and Zohra Lomri, bringing their extensive expertise in research and drug development to the forefront. Participants can look forward to not just a theoretical overview, but practical advice aimed at overcoming common challenges in real-world settings, from assay platform selection to standardizing sample collection across various sites.

Who Should Attend?

This webinar is ideal for biotech and biopharma professionals who are involved in the development of oncology treatments. It offers invaluable strategies for adopting MRD into their clinical plans effectively. It is an opportunity to shift from theoretical knowledge to actionable insights in the application of MRD, regardless of whether you are at the planning stage or in the midst of a clinical trial.

Registration Details

The live session will take place on May 6, 2026, at 11 AM EDT (5 PM CEST). To register for this pivotal discussion, please visit Xtalks Webinar Registration.

By attending this webinar, you'll not only gain clarity on integrating MRD into oncology programs but also learn how to collaborate effectively with a strategic Clinical Research Organization (CRO) to operationalize MRD in global studies. Join the community of life science professionals and ensure your approach to MRD is both informed and forward-thinking.

About Xtalks

Xtalks is a premier platform for the life science industry, dedicated to providing professionals with the tools and knowledge needed to thrive in the field. From insightful webinars to comprehensive articles and resources, Xtalks is committed to supporting informed decision-making and continuous learning.

For more information, visit Xtalks or contact Vera Kovacevic at +1 (416) 977-6555 x371.